ライフサイエンスコーパス: ankylosing spondylitis

1 pus erythematosus, rheumatoid arthritis, and ankylosing spondylitis.

2 ists are effective for signs and symptoms of ankylosing spondylitis.

3 s and spinal deformities similar to those in ankylosing spondylitis.

4 en shown to be effective in the treatment of ankylosing spondylitis.

5 dissection of the genetic susceptibility to ankylosing spondylitis.

6 otential role in delaying the progression of ankylosing spondylitis.

7 itis and to attenuate spinal inflammation in ankylosing spondylitis.

8 antagonists can prevent structural damage in ankylosing spondylitis.

9 b were also effective in phase III trials in ankylosing spondylitis.

10 thritis can be asymptomatic, as in classical ankylosing spondylitis.

11 or (p75):Fc fusion protein, in patients with ankylosing spondylitis.

12 , and sustained improvement in patients with ankylosing spondylitis.

13 in Sardinia, seem not to be associated with ankylosing spondylitis.

14 ondyloarthropathies, psoriatic arthritis and ankylosing spondylitis.

15 children or siblings of female patients with ankylosing spondylitis.

16 rials of secukinumab in patients with active ankylosing spondylitis.

17 ording to the modified New York criteria for ankylosing spondylitis.

18 s Crohn's disease, rheumatoid arthritis, and ankylosing spondylitis.

19 e epistatic association of both molecules in ankylosing spondylitis.

20 icrobiome are associated with development of ankylosing spondylitis.

21 orm of axial spondyloarthropathies, which is ankylosing spondylitis.

22 -7.0) for psoriasis, psoriatic arthritis, or ankylosing spondylitis.

23 -B27 subtypes differentially associated with ankylosing spondylitis.

24 inflammatory diseases, notably psoriasis and ankylosing spondylitis.

25 th inflammatory bowel disease, psoriasis and ankylosing spondylitis.

26 f exercise and nonpharmacologic therapies in ankylosing spondylitis.

27 on may be of benefit to select patients with ankylosing spondylitis.

28 psoriatic arthritis, reactive arthritis, or ankylosing spondylitis.

29 espect to understanding the genetic basis of ankylosing spondylitis.

30 ythematosus (1346+/-1011 pg per milliliter), ankylosing spondylitis (1368+/-1162 pg per milliliter),

31 ges of patients achieving the Assessments in Ankylosing Spondylitis 20% response (ASAS20) at weeks 12

32 improved significantly after MR imaging for ankylosing spondylitis (29% vs 80%, P < .001), undiffere

33 ren of women had an even higher incidence of ankylosing spondylitis (7.2 [1.5-34], p=0.013) than did

34 relationship between the gut microbiome and ankylosing spondylitis, a quantitative metagenomics stud

35 Evaluating Long-Term Efficacy and Safety in Ankylosing Spondylitis, a randomized controlled study, w

36 ot disease and valve disease associated with ankylosing spondylitis (AKS).

37 Reactive arthritis, sacroiliitis, and ankylosing spondylitis also appear to be increased in th

38 residues 528 and 575/725 is associated with ankylosing spondylitis among HLA-B27-positive individual

39 riteria for PsA, a new composite measure for ankylosing spondylitis and axial SpA, the ASDAS, new mea

40 ndyloarthropathic changes closely resembling ankylosing spondylitis and DISH.

41 dies of various physical therapy programs in ankylosing spondylitis and identify their benefits and p

42 has supported novel roles for these drugs in ankylosing spondylitis and in cancer prevention, accumul

43 ecent studies indicate that the morbidity of ankylosing spondylitis and PsA are considerably higher t

44 Three risk loci shared with ankylosing spondylitis and psoriasis (the MHC class I re

45 uding rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriasis, confirms the impor

46 clude rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriasis.

47 immune-mediated disorders, most notably with ankylosing spondylitis and psoriasis.

48 of the tumor necrosis factor antagonists in ankylosing spondylitis and psoriatic arthritis has gener

49 necrosis factor inhibitors for patients with ankylosing spondylitis and psoriatic arthritis has had a

50 Sulfasalazine is moderately effective for ankylosing spondylitis and psoriatic arthritis, although

51 The greatest experience has accrued in ankylosing spondylitis and psoriatic arthritis.

52 ved functional status and quality of life in ankylosing spondylitis and psoriatic arthritis.

53 als with tumor necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis.

54 are effective and safe for the treatment of ankylosing spondylitis and psoriatic arthritis.

55 cells from healthy donors and patients with ankylosing spondylitis and psoriatic arthritis.

56 Ankylosing spondylitis and related spondylarthritides ar

57 ole for HLA-B27 in genetic susceptibility to ankylosing spondylitis and related spondyloarthropathies

58 patients with systemic lupus erythematosus, ankylosing spondylitis, and hepatic fibrosis.

59 anding inflammation in rheumatoid arthritis, ankylosing spondylitis, and juvenile chronic arthritis.

60 tion may have structure-modifying effects in ankylosing spondylitis, and may thereby alter the diseas

61 immune diseases such as behcet's disease and ankylosing spondylitis, and ocular involvement of infect

62 nvestigated one in detail, a risk allele for ankylosing spondylitis, and provide direct evidence of a

63 py not only in RA but also in Crohn disease, ankylosing spondylitis, and several other chronic inflam

64 lgia rheumatica (PMR), giant cell arteritis, ankylosing spondylitis, and Sjogren's syndrome, and to p

65 e of the spondyloarthritides, including PsA, ankylosing spondylitis, and the broader categories of Sp

66 the disease-modifying role of these drugs in ankylosing spondylitis, and their use in the understudie

67 s, two patients with gout, two patients with ankylosing spondylitis, and two patients with psoriatic

68 Patients with juvenile-onset ankylosing spondylitis appear to have poorer functional

69 or rheumatoid arthritis, where patients with ankylosing spondylitis are offered therapy early in the

70 The spondylarthritides (such as ankylosing spondylitis) are multisystem inflammatory dis

71 This group includes 6 entities: ankylosing spondylitis, arthritis associated with inflam

72 h American sample of two new loci related to ankylosing spondylitis, ARTS1 and IL23R, and confirmatio

73 systemic lupus erythematosus (SLE) (n = 10), ankylosing spondylitis (AS) (n = 10), primary Sjogren's

74 Ankylosing spondylitis (AS) affects 0.25-1.0% of the pop

75 s detailing their application in a number of ankylosing spondylitis (AS) and axial spondyloarthritis

76 mography (MDCT) findings of 41 patients with ankylosing spondylitis (AS) and compared them with pulmo

77 e autoimmune inflammatory arthritis disorder ankylosing spondylitis (AS) and with other related spond

78 Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are chronic inflammatory dis

79 ) affects approximately 40% of patients with ankylosing spondylitis (AS) but also affects patients wi

80 nk/ank mouse develops a phenotype similar to ankylosing spondylitis (AS) in humans.

81 tients with MRI-evident sacroiliitis develop ankylosing spondylitis (AS) in the long term and whether

82 Ankylosing spondylitis (AS) is a chronic inflammatory ar

83 Ankylosing spondylitis (AS) is a common and highly famil

84 Ankylosing spondylitis (AS) is a common, highly heritabl

85 We investigated the proposal that ankylosing spondylitis (AS) is associated with unusual E

86 Ankylosing spondylitis (AS) may present with extra-artic

87 The clinical response in ankylosing spondylitis (AS) patients treated with biolog

88 ment of spinal inflammation in patients with ankylosing spondylitis (AS) relies primarily on magnetic

89 udies of the HLA-B27-transgenic rat model of ankylosing spondylitis (AS) suggested that macrophages d

90 A strong association between ERAP1 and ankylosing spondylitis (AS) was recently identified by t

91 7 subtypes associated with susceptibility to ankylosing spondylitis (AS), and those reported not to b

92 HC) tag SNPs from 1,000 independent cases of ankylosing spondylitis (AS), autoimmune thyroid disease

93 s I molecule B27 is strongly associated with ankylosing spondylitis (AS), but the pathogenic role of

94 rated high heritability of susceptibility to ankylosing spondylitis (AS), it is only recently that th

95 ld standard of rheumatologists' diagnosis of ankylosing spondylitis (AS), psoriatic arthritis (PsA),

96 l and peripheral articular manifestations of ankylosing spondylitis (AS), psoriatic arthritis (PsA),

97 endoplasmic reticulum aminopeptidase 1) with ankylosing spondylitis (AS), which is restricted to HLA-

98 l disease with rheumatoid arthritis (RA) and ankylosing spondylitis (AS).

99 lity of life (HRQOL) in patients with active ankylosing spondylitis (AS).

100 pathogenic role in the spondylarthropathy of ankylosing spondylitis (AS).

101 sulfapyridine (SP), in patients with active ankylosing spondylitis (AS).

102 e treatment of osteoporosis in patients with ankylosing spondylitis (AS).

103 ss I molecules due to their association with Ankylosing Spondylitis (AS).

104 hat is necessary to establish a diagnosis of ankylosing spondylitis (AS).

105 graphic damage in patients with longstanding ankylosing spondylitis (AS).

106 ciated with the chronic inflammatory disease Ankylosing Spondylitis (AS); however, the mechanisms und

107 ASsessment of Ankylosing Spondylitis (ASAS) International Working Grou

108 with unlike conformations in differentially ankylosing spondylitis-associated subtypes) must not be

109 initiate autoimmune damage in patients with ankylosing spondylitis-associated subtypes.

110 cant reductions in the signs and symptoms of ankylosing spondylitis at week 16.

111 a prospective study involving patients with ankylosing spondylitis, behcet's disease, presumed sarco

112 e for relieving the pain of axial disease in ankylosing spondylitis but these findings contradict two

113 me-wide association study in 2,053 unrelated ankylosing spondylitis cases among people of European de

114 replication in an independent cohort of 898 ankylosing spondylitis cases and 1,518 controls.

115 changes in the course of the disease, Stoke Ankylosing spondylitis classification Spinal Score (SASS

116 eously investigated the genetic landscape of ankylosing spondylitis, Crohn's disease, psoriasis, prim

117 D16S516), multiple sclerosis (D12S1052), and ankylosing spondylitis (D16S516).

118 0 patients and 45 controls: alopecia areata, ankylosing spondylitis, dermatomyositis, Graves' disease

119 oth M-CSF and MMP-3 correlated with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) v

120 onset, disease activity assessed by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),

121 ondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),

122 cal disease activity as measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),

123 Disease activity was assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).

124 ter disease activity as measured by the Bath Ankylosing Spondylitis Disease Activity Index (P = 0.002

125 nthesitis (using the PsA-modified Maastricht Ankylosing Spondylitis Enthesitis Score [MASES] index).

126 ce of rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, familial Mediterranean fever, an

127 rmatomyositis; 16 had scleroderma; eight had ankylosing spondylitis; five had juvenile RA; three had

128 ose with psoriatic arthritis, and those with ankylosing spondylitis from phase III trials of golimuma

129 al assessments included the BASDAI, the Bath Ankylosing Spondylitis Functional Index (BASFI), the Ank

130 ght, VAS scores for entheseal pain, the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bat

131 d functional impairment assessed by the Bath Ankylosing Spondylitis Functional Index (BASFI).

132 nal limitations were assessed using the Bath Ankylosing Spondylitis Functional Index (BASFI; score ra

133 etween inflammation and structural damage in ankylosing spondylitis has been an important focus of re

134 Medical therapy of ankylosing spondylitis has improved dramatically with th

135 ive arthritis, but an infectious trigger for ankylosing spondylitis has not yet been established.

136 d for patients with rheumatoid arthritis and ankylosing spondylitis have been reported, and generic q

137 esitis in psoriatic arthritis and uveitis in ankylosing spondylitis, have also been observed.

138 at has been shown to control the symptoms of ankylosing spondylitis in a phase 2 trial.

139 x in determining increased susceptibility to ankylosing spondylitis in children.

140 that TNFi slows radiographic progression in ankylosing spondylitis in data from clinical trials may

141 osome regions in human genome, which control ankylosing spondylitis in human patients.

142 irst published clinical account of a case of ankylosing spondylitis in the United States.

143 principle has relevance to diseases such as ankylosing spondylitis, in which HLA-B27 and ERAP jointl

144 une hemolytic anemia, pernicious anemia, and ankylosing spondylitis), infectious (pneumonia, hepatiti

145 f Life (ASQoL) instrument, the ASsessment in Ankylosing Spondylitis International Working Group crite

146 Ankylosing spondylitis is a common form of inflammatory

147 Ankylosing spondylitis is a genetically determined and c

148 Ankylosing spondylitis is an inflammatory autoimmune dis

149 Ankylosing spondylitis is associated with increased risk

150 IL-1A association further substantiate that ankylosing spondylitis is determined to a large extent b

151 modified New York criteria, the diagnosis of ankylosing spondylitis is made based on the presence of

152 Nearly half of the susceptibility to ankylosing spondylitis is provided by major histocompati

153 One of the major goals of treatment of ankylosing spondylitis is to prevent or slow the develop

154 autoimmune disease and evidence showed that ankylosing spondylitis may be a microbiome-driven diseas

155 = 8), juvenile rheumatoid arthritis (n = 3), ankylosing spondylitis (n = 1), and psoriatic spondylart

156 , rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-infectious uveitis, and mult

157 d arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, or inflammatory bowel disease us

158 d IL12B regions convincingly associated with ankylosing spondylitis (P < 5 x 10(-8) in the combined d

159 tients with presumed sarcoidosis compared to ankylosing spondylitis (p = 0.0001), behcet's disease (p

160 ts with presumed sarcoidosis with respect to ankylosing spondylitis (p = 0.0001), behcet's disease, (

161 dation of two new genes, IL23R and ARTS1, in ankylosing spondylitis pathogenesis.

162 shown to be differentially abundant between ankylosing spondylitis patients and healthy controls.

163 A recent trial in ankylosing spondylitis patients demonstrated continuous

164 Specifically, the ankylosing spondylitis patients demonstrated increases i

165 monly used in probiotics, accumulated in the ankylosing spondylitis patients.

166 emic sclerosis patients and in 3 of 12 (25%) ankylosing spondylitis patients.

167 e advances in the pharmacological therapy of ankylosing spondylitis, physical therapy remains an esse

168 carrying of the spinal cord in the course of ankylosing spondylitis, present in MRI include: bone mar

169 n the pathogenesis or development process of ankylosing spondylitis, providing new leads for the deve

170 IBD), and psoriasis, psoriatic arthritis, or ankylosing spondylitis (psoriasis and spondyloarthropath

171 Group criteria for SpA, without evidence of ankylosing spondylitis, psoriasis, inflammatory bowel di

172 ct in the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and juvenil

173 ts and for diseases other than RA, including ankylosing spondylitis, psoriatic arthritis, and polymyo

174 uded in the category of spondyloarthropathy (ankylosing spondylitis, psoriatic arthritis, reactive ar

175 ng Spondylitis Functional Index (BASFI), the Ankylosing Spondylitis Quality of Life (ASQoL) instrumen

176 the Short Form 36 (SF-36) Health Survey and Ankylosing Spondylitis Quality of Life (ASQoL) Questionn

177 tis Disease Activity Index (BASDAI), and the Ankylosing Spondylitis Quality of Life (ASQoL) questionn

178 lvis, and hips were scored by using the Bath Ankylosing Spondylitis Radiology Index (BASRI) by an exp

179 pinal radiographs were scored using the Bath Ankylosing Spondylitis Radiology Index for the spine (BA

180 ry rheumatic diseases that primarily include ankylosing spondylitis, reactive arthritis, and the arth

181 rheumatological conditions (i.e. psoriasis, ankylosing spondylitis, rheumatoid arthritis, fibromyalg

182 dy reports four genetic loci associated with ankylosing spondylitis risk and identifies a major role

183 before HLA class I presentation, only affect ankylosing spondylitis risk in HLA-B27-positive individu

184 ) a random sample of members of the National Ankylosing Spondylitis Society.

185 bar spine, which were scored using the Stoke Ankylosing Spondylitis Spine Score.

186 of the interleukin-1 (IL-1) region genes in ankylosing spondylitis suggested the susceptibility to b

187 A recent meta-analysis of published scans of ankylosing spondylitis susceptibility has confirmed site

188 on-major histocompatibility complex genes in ankylosing spondylitis susceptibility, and suggests area

189 ocompatibility complex), 10q, 16q and 19q in ankylosing spondylitis susceptibility.

190 nt GWAS on multiple sclerosis, psoriasis and ankylosing spondylitis that inclusion of known covariate

191 able and effective structure modification in ankylosing spondylitis, the data strongly suggest a bene

192 As in human ankylosing spondylitis, the MHC was the major permissive

193 ide strong evidence that HLA-B27 operates in ankylosing spondylitis through a mechanism involving abe

194 Exercise therapy should remain a mainstay of ankylosing spondylitis treatment complementing medical t

195 durations may result in a paradigm shift for ankylosing spondylitis treatment similar to that undergo

196 Ankylosing spondylitis was more prevalent among children

197 To identify susceptibility loci for ankylosing spondylitis, we undertook a genome-wide assoc

198 50% and 75% of patients were diagnosed with ankylosing spondylitis were ascertained from a database

199 Forty patients with active, inflammatory ankylosing spondylitis were randomly assigned to receive

200 e SpA (2 with psoriatic arthritis and 1 with ankylosing spondylitis) were isolated by positive select

201 cantly reduces spinal inflammation in active ankylosing spondylitis when compared to placebo; there w

202 There are few effective treatments for ankylosing spondylitis, which causes substantial morbidi

203 atibility complex genes in predisposition to ankylosing spondylitis, which will be summarized here.

204 and women differ in their susceptibility to ankylosing spondylitis, with about 2.5 men affected for

205 de over 90% of the overall susceptibility to ankylosing spondylitis, with about half of the genetic c

206 esitis-related arthritis progress to develop ankylosing spondylitis within 10 years after presentatio